MXPA02005602A - Compuestos de urea que tienen actividad antagonista para el receptor muscarinico. - Google Patents
Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.Info
- Publication number
- MXPA02005602A MXPA02005602A MXPA02005602A MXPA02005602A MXPA02005602A MX PA02005602 A MXPA02005602 A MX PA02005602A MX PA02005602 A MXPA02005602 A MX PA02005602A MX PA02005602 A MXPA02005602 A MX PA02005602A MX PA02005602 A MXPA02005602 A MX PA02005602A
- Authority
- MX
- Mexico
- Prior art keywords
- muscarinic receptor
- receptor antagonist
- antagonist activity
- urea compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
0Esta invencion se relaciona con derivados de carbamato impedidos que son antagonistas para el receptor muscarinico y con composiciones farmaceuticas antagonistas que comprenden tales compuestos asi como con metodos para preparar estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45617099A | 1999-12-07 | 1999-12-07 | |
PCT/US2000/033155 WO2001042213A1 (en) | 1999-12-07 | 2000-12-07 | Urea compounds having muscarinic receptor antagonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02005602A true MXPA02005602A (es) | 2004-09-10 |
Family
ID=23811737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02005602A MXPA02005602A (es) | 1999-12-07 | 2000-12-07 | Compuestos de urea que tienen actividad antagonista para el receptor muscarinico. |
Country Status (27)
Country | Link |
---|---|
US (3) | US6635764B2 (es) |
EP (2) | EP1235803B1 (es) |
JP (1) | JP2003516391A (es) |
KR (1) | KR100748150B1 (es) |
CN (1) | CN1271054C (es) |
AT (2) | ATE439345T1 (es) |
AU (1) | AU782232B2 (es) |
BR (1) | BR0015963A (es) |
CA (1) | CA2392030C (es) |
CZ (1) | CZ20021830A3 (es) |
DE (2) | DE60012223T2 (es) |
EA (1) | EA006437B1 (es) |
ES (3) | ES2243333T3 (es) |
HK (1) | HK1049483B (es) |
HR (1) | HRP20020574B1 (es) |
HU (1) | HUP0203677A2 (es) |
IL (2) | IL149289A0 (es) |
IS (1) | IS2191B (es) |
MX (1) | MXPA02005602A (es) |
NO (1) | NO323544B1 (es) |
NZ (1) | NZ518722A (es) |
PL (1) | PL364922A1 (es) |
SK (1) | SK7982002A3 (es) |
UA (1) | UA73543C2 (es) |
WO (1) | WO2001042213A1 (es) |
YU (1) | YU42402A (es) |
ZA (2) | ZA200204553B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
JP2006502985A (ja) | 2002-07-08 | 2006-01-26 | ランバクシー ラボラトリーズ リミテッド | ムスカリン性受容体拮抗剤として有用な3,6−二置換アザビシクロ[3.1.0]ヘキサン誘導体 |
CN100364990C (zh) * | 2002-10-30 | 2008-01-30 | 施万制药 | 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物 |
TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
CN101239968B (zh) * | 2003-02-14 | 2011-07-20 | 施万制药 | 联苯衍生物 |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
AU2004228028B2 (en) * | 2003-04-03 | 2009-12-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
US7517905B2 (en) | 2003-04-09 | 2009-04-14 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
BRPI0409302A (pt) | 2003-04-11 | 2006-04-11 | Ranbaxy Lab Ltd | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
JP2007518677A (ja) * | 2003-06-23 | 2007-07-12 | シーブイ・セラピューティクス・インコーポレイテッド | 脂肪酸酸化インヒビターとしてのピペラジンおよびピペリジンのウレア誘導体 |
WO2005007645A1 (en) * | 2003-07-11 | 2005-01-27 | Theravance, Inc. | Substituted 4-amino-1-benzylpiperidine compounds |
UY28538A1 (es) * | 2003-09-26 | 2005-04-29 | Vertex Pharma | Derivados de fenil-piperazina como moduladores de receptores muscarínicos |
PE20050973A1 (es) * | 2003-10-29 | 2005-11-19 | Theravance Inc | Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos |
US7345060B2 (en) | 2003-11-21 | 2008-03-18 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
US7320990B2 (en) | 2004-02-13 | 2008-01-22 | Theravance, Inc. | Crystalline form of a biphenyl compound |
US7501442B2 (en) * | 2004-03-11 | 2009-03-10 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
US7560469B2 (en) * | 2004-03-11 | 2009-07-14 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
TW200538095A (en) * | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
WO2005087733A1 (en) * | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
EP1723112A1 (en) * | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
JP2007528413A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
US7456199B2 (en) * | 2004-03-11 | 2008-11-25 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
US7618936B2 (en) * | 2004-05-21 | 2009-11-17 | The Regents Of The University Of California | Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1) |
WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
EP1778626A1 (en) * | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
CN101084216B (zh) * | 2004-10-20 | 2011-09-14 | 加利福尼亚大学董事会 | 可溶性环氧化物水解酶的改进抑制剂 |
WO2006058294A2 (en) | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
GB0503054D0 (en) * | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
WO2006099031A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
US7659403B2 (en) | 2005-03-10 | 2010-02-09 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
TW200714587A (en) * | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
US7642355B2 (en) * | 2005-03-10 | 2010-01-05 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
WO2006099032A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
TWI372749B (en) * | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
WO2006105035A2 (en) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
EP1893577A1 (en) | 2005-06-13 | 2008-03-05 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
AU2006305619A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
US7973055B2 (en) * | 2006-03-09 | 2011-07-05 | Theravance, Inc. | Crystalline forms of a biphenyl compound |
TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
CN101605784B (zh) * | 2007-02-09 | 2013-04-10 | 安斯泰来制药株式会社 | 氮杂桥环化合物 |
US8017617B2 (en) * | 2007-12-14 | 2011-09-13 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
AU2010239522B2 (en) | 2009-04-23 | 2015-07-02 | Theravance Biopharma R&D Ip, Llc | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
RU2013118026A (ru) * | 2010-10-20 | 2014-10-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Карбонатные производные для лечения кашля |
JP6021616B2 (ja) * | 2012-12-04 | 2016-11-09 | 株式会社アエタスファルマ | 3−ピペラジニル−1−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物 |
KR101514320B1 (ko) * | 2013-06-14 | 2015-04-22 | 재단법인 의약바이오컨버젼스연구단 | 신규한 암 예방 또는 치료용 약학적 조성물 |
ME03438B (me) | 2014-06-06 | 2020-01-20 | Astellas Pharma Inc | DERIVAT 2-ACILAMINOTIAZOLA ZA UPOTREBU U PREVENCIJI ILI LEčENJU OBOLJENJA BESIKE / URINARNOG TRAKTA |
US20210355114A1 (en) * | 2018-10-24 | 2021-11-18 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
US20220204497A1 (en) * | 2019-03-29 | 2022-06-30 | Medicinal Bioconvergence Research Center | Novel compound having anticancer activity, and method for producing same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE3402060A1 (de) | 1984-01-21 | 1985-08-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4675326A (en) | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
DK443489D0 (da) | 1989-09-08 | 1989-09-08 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
WO1993020071A1 (en) * | 1992-03-31 | 1993-10-14 | Glaxo Group Limited | Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
AU7545894A (en) * | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
HUT76289A (en) | 1994-02-10 | 1997-07-28 | Yamanouchi Pharma Co Ltd | Carbamate derivative and medicinal composition containing the same |
US5691323A (en) | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
CA2234619A1 (en) | 1995-10-13 | 1997-04-17 | Morihiro Mitsuya | Substituted heteroaromatic ring derivatives |
WO1998000141A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-trihexyphenidyl |
US6500934B1 (en) | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
US6062766A (en) * | 1997-08-04 | 2000-05-16 | Quixote Corporation | Raised pavement marker |
CA2313125A1 (en) | 1997-12-12 | 1999-06-24 | Laramie Mary Gaster | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
US6086881A (en) * | 1998-05-15 | 2000-07-11 | Children's Medical Center Corp. | Spatially aligned conjugated composition having a thioether bond linkage |
US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
MXPA02005596A (es) * | 1999-12-07 | 2004-09-10 | Theravance Inc | Derivados de carbamato con actividad antagonista para el rerceptor muscarinico. |
UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
US20020049152A1 (en) * | 2000-06-19 | 2002-04-25 | Zyomyx, Inc. | Methods for immobilizing polypeptides |
-
2000
- 2000-07-12 UA UA2002075566A patent/UA73543C2/uk unknown
- 2000-12-07 PL PL00364922A patent/PL364922A1/xx not_active Application Discontinuation
- 2000-12-07 MX MXPA02005602A patent/MXPA02005602A/es active IP Right Grant
- 2000-12-07 AT AT04012859T patent/ATE439345T1/de not_active IP Right Cessation
- 2000-12-07 IL IL14928900A patent/IL149289A0/xx active IP Right Grant
- 2000-12-07 US US09/732,514 patent/US6635764B2/en not_active Expired - Lifetime
- 2000-12-07 CZ CZ20021830A patent/CZ20021830A3/cs unknown
- 2000-12-07 ES ES00983991T patent/ES2243333T3/es not_active Expired - Lifetime
- 2000-12-07 AT AT00982493T patent/ATE271039T1/de not_active IP Right Cessation
- 2000-12-07 ES ES00982493T patent/ES2225275T3/es not_active Expired - Lifetime
- 2000-12-07 BR BR0015963-8A patent/BR0015963A/pt not_active Application Discontinuation
- 2000-12-07 HU HU0203677A patent/HUP0203677A2/hu unknown
- 2000-12-07 EP EP00982493A patent/EP1235803B1/en not_active Expired - Lifetime
- 2000-12-07 CN CNB008167028A patent/CN1271054C/zh not_active Expired - Lifetime
- 2000-12-07 DE DE60012223T patent/DE60012223T2/de not_active Expired - Lifetime
- 2000-12-07 KR KR1020027007147A patent/KR100748150B1/ko active IP Right Grant
- 2000-12-07 SK SK798-2002A patent/SK7982002A3/sk unknown
- 2000-12-07 EA EA200200646A patent/EA006437B1/ru not_active IP Right Cessation
- 2000-12-07 YU YU42402A patent/YU42402A/sh unknown
- 2000-12-07 JP JP2001543514A patent/JP2003516391A/ja active Pending
- 2000-12-07 CA CA002392030A patent/CA2392030C/en not_active Expired - Lifetime
- 2000-12-07 AU AU19518/01A patent/AU782232B2/en not_active Expired
- 2000-12-07 ES ES04012859T patent/ES2329785T3/es not_active Expired - Lifetime
- 2000-12-07 NZ NZ518722A patent/NZ518722A/en not_active IP Right Cessation
- 2000-12-07 DE DE60042762T patent/DE60042762D1/de not_active Expired - Lifetime
- 2000-12-07 WO PCT/US2000/033155 patent/WO2001042213A1/en not_active Application Discontinuation
- 2000-12-07 EP EP04012859A patent/EP1457488B1/en not_active Expired - Lifetime
-
2002
- 2002-04-23 IL IL149289A patent/IL149289A/en unknown
- 2002-04-26 IS IS6362A patent/IS2191B/is unknown
- 2002-06-06 NO NO20022683A patent/NO323544B1/no not_active IP Right Cessation
- 2002-06-06 ZA ZA200204553A patent/ZA200204553B/en unknown
- 2002-06-06 ZA ZA200204557A patent/ZA200204557B/en unknown
- 2002-07-04 HR HR20020574A patent/HRP20020574B1/xx not_active IP Right Cessation
-
2003
- 2003-03-03 HK HK03101572.1A patent/HK1049483B/zh not_active IP Right Cessation
- 2003-04-30 US US10/426,364 patent/US20040054187A1/en not_active Abandoned
- 2003-04-30 US US10/426,270 patent/US20040116706A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02005602A (es) | Compuestos de urea que tienen actividad antagonista para el receptor muscarinico. | |
MXPA02005596A (es) | Derivados de carbamato con actividad antagonista para el rerceptor muscarinico. | |
WO2000073307A3 (en) | Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors | |
IL155806A0 (en) | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | |
HUP0500107A3 (en) | 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists | |
IL157093A0 (en) | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists | |
HUP0200803A2 (hu) | Integrin antagonistákként alkalmazható, helyettesített kétgyűrűs heteroaril vegyületek, az azokat tartalmazó gyógyászati készítmények és az intermedierek | |
AU6011301A (en) | 1,2,3,4-tetrahydroisoquinoline derivatives | |
IL162851A0 (en) | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists | |
EP1244452A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
HUP0201571A3 (en) | Il-8 receptor antagonist phenyl urea derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
HUP0200281A3 (en) | Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them | |
AU1092800A (en) | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists | |
IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
HUP0201710A2 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them | |
EP1246619A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
WO2001029066A3 (en) | Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them | |
HUP0200080A3 (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists and pharmaceutical compositions containing the compounds | |
HUP0303513A3 (en) | Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them | |
HUP0202710A3 (en) | Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use | |
MY117975A (en) | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists | |
MY121063A (en) | Use of nmda antagonists for treatment of irritable bowel syndrome | |
DE69526738D1 (de) | Endothelin-rezeptor-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |